$10.94
0.09%
Nasdaq, Sep 25, 04:01 pm EDT. Closed.
ISIN
US38341P1021
Symbol
GOSS

Gossamer Bio, Inc. Target price 2026 - Analyst rating & recommendation

Gossamer Bio, Inc. Classifications & Recommendation

Buy
64%
Hold
29%
Sell
7%

Gossamer Bio, Inc. Price Target

Target Price $1.53
Price $10.94
Deviation
Number of Estimates 8
8 Analysts have issued a price target Gossamer Bio, Inc. 2027 . The average Gossamer Bio, Inc. target price is $1.53. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 14 analysts: 9 Analysts recommend Gossamer Bio, Inc. to buy, 4 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Gossamer Bio, Inc. stock has an average upside potential 2027 of . Most analysts recommend the Gossamer Bio, Inc. stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ 48.47 33.71
57.74% 30.45%
EBITDA Margin -336.77% -292.87%
553.70% 13.03%
Net Margin -351.50% -429.41%
613.19% 22.17%

9 Analysts have issued a sales forecast Gossamer Bio, Inc. 2026 . The average Gossamer Bio, Inc. sales estimate is

$33.7m
unlock
. This is
36.74% lower
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$46.8m 12.27%
unlock
, the lowest is
$25.7m 51.84%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $48.5m 57.74%
2026
$33.7m 30.45%
unlock
2027
$50.7m 50.52%
unlock
2028
$85.9m 69.28%
unlock
2029
$246m 186.82%
unlock
2030
$359m 45.68%
unlock
2031
$487m 35.57%
unlock
2032
$538m 10.53%
unlock
2033
$660m 22.69%
unlock

3 Analysts have issued an Gossamer Bio, Inc. EBITDA forecast 2026. The average Gossamer Bio, Inc. EBITDA estimate is

$-98.7m
unlock
. This is
37.75% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-102m 35.91%
unlock
, the lowest is
$-94.9m 40.19%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $-163m 176.24%
2026
$-98.7m 39.51%
unlock
2027
$-138m 39.88%
unlock
2028
$-156m 13.00%
unlock
2029
$-25.8m 83.46%
unlock
2030
$39.1m 251.38%
unlock
2031
$131m 234.20%
unlock

EBITDA Margin

2025 -336.77% 553.70%
2026
-292.87% 13.03%
unlock
2027
-272.16% 7.07%
unlock
2028
-181.67% 33.25%
unlock
2029
-10.47% 94.24%
unlock
2030
10.88% 203.92%
unlock
2031
26.83% 146.60%
unlock

9 Gossamer Bio, Inc. Analysts have issued a net profit forecast 2026. The average Gossamer Bio, Inc. net profit estimate is

$-145m
unlock
. This is
15.61% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-118m 5.72%
unlock
, the lowest is
$-187m 49.21%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-170m 201.38%
2026
$-145m 15.03%
unlock
2027
$-51.2m 64.64%
unlock
2028
$-61.8m 20.79%
unlock
2029
$97.7m 258.06%
unlock
2030
$120m 22.45%
unlock
2031
$189m 58.34%
unlock
2032
$297m 56.58%
unlock
2033
$386m 30.25%
unlock

Net Margin

2025 -351.50% 613.19%
2026
-429.41% 22.17%
unlock
2027
-100.88% 76.51%
unlock
2028
-71.98% 28.65%
unlock
2029
39.67% 155.11%
unlock
2030
33.34% 15.96%
unlock
2031
38.94% 16.80%
unlock
2032
55.16% 41.65%
unlock
2033
58.56% 6.16%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -0.75 -0.30
200.00% 60.00%
P/E negative
EV/Sales 1.36

9 Analysts have issued a Gossamer Bio, Inc. forecast for earnings per share. The average Gossamer Bio, Inc. EPS is

$-0.30
unlock
. This is
21.05% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.24 36.84%
unlock
, the lowest is
$-0.38 0.00%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.75 200.00%
2026
$-0.30 60.00%
unlock
2027
$-0.10 66.67%
unlock
2028
$-0.13 30.00%
unlock
2029
$0.20 253.85%
unlock
2030
$0.24 20.00%
unlock
2031
$0.39 62.50%
unlock
2032
$0.61 56.41%
unlock
2033
$0.79 29.51%
unlock

P/E ratio

Current -28.79 475.79%
2026
-36.94 28.31%
unlock
2027
-104.47 182.81%
unlock
2028
-86.50 17.20%
unlock
2029
54.72 163.26%
unlock
2030
44.69 18.33%
unlock
2031
28.22 36.85%
unlock
2032
18.03 36.11%
unlock
2033
13.84 23.24%
unlock

Based on analysts' sales estimates for 2026, the Gossamer Bio, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.86 94.90%
2026
1.36 58.56%
unlock
2027
0.91 33.57%
unlock
2028
0.54 40.93%
unlock
2029
0.19 65.13%
unlock
2030
0.13 31.35%
unlock
2031
0.09 26.23%
unlock
2032
0.09 9.52%
unlock
2033
0.07 18.48%
unlock

P/S ratio

Current 1.25 92.72%
2026
1.98 58.06%
unlock
2027
1.32 33.57%
unlock
2028
0.78 40.92%
unlock
2029
0.27 65.14%
unlock
2030
0.19 31.37%
unlock
2031
0.14 26.21%
unlock
2032
0.12 9.53%
unlock
2033
0.10 18.50%
unlock

Current Gossamer Bio, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
➜
Locked
Locked Sep 21 2026
Piper Sandler
Locked
➜
Locked
Locked Aug 14 2026
Leerink Partners
Locked
➜
Locked
Locked Jul 28 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Jul 27 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Jun 25 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked May 26 2026
Barclays
Locked
➜
Locked
Locked May 19 2026
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Sep 21 2026
Locked
Piper Sandler:
Locked
➜
Locked
Aug 14 2026
Locked
Leerink Partners:
Locked
➜
Locked
Jul 28 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Jul 27 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Jun 25 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
May 26 2026
Locked
Barclays:
Locked
➜
Locked
May 19 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today